# National Heart, Lung, and Blood Institute (NHLBI): Phase 3 study started recruiting, 210 planned (Allogeneic Stem Cell Transplantation, Lung Allograft Transplantation)

**Score:** 85/100

| Field | Value |
|---|---|
| Sponsor | National Heart, Lung, and Blood Institute (NHLBI) |
| Sponsor type | NIH |
| Study | Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging |
| NCT ID | NCT07613099 |
| Phase | Phase 3 |
| Status | recruiting |
| Conditions | Allogeneic Stem Cell Transplantation; Lung Allograft Transplantation; Interstitial Lung Disease; Acute Lung Injury; Pulmonary Arterial Hypertension; Cardiovascular Diseases |
| Intervention types | drug, diagnostic test |
| Target enrollment | 210 |
| Site countries | United States |
| Posted | 2026-05-29 |
| Planned start | 2026-09-18 |
| Event | Started recruiting |
| Event date | 2026-09-18 |
| Last update posted | 2026-10-26 |

## Why this score
- Posted in the last two weeks.
- Just started recruiting: sites, recruitment and supply are active.
- Phase 3: multi-site, larger budget.
- 210 participants planned.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07613099). Last refreshed: 2026-11-04T06:04:38.232Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.